专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR20180009639A 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물 审中-公开
标题翻译：用于治疗或预防包含Midkine抑制剂的脑肿瘤的药物组合物
公开(公告)号：KR20180009639A
公开(公告)日：2018-01-29
申请号：KR20160091625
申请日：2016-07-19
申请人： SAMSUNG ELECTRONICS CO LTD , SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： OH JIN MI , NAM DO HYUN , KANG HYUN JU , KIM SEA HEE , HAN SU JI , KONG DOO SIK
IPC分类号： A61K38/18 , A61K31/4188 , A61K39/00 , A61K39/395 , G01N33/50 , G01N33/574
CPC分类号： A61K31/4188 , A61K38/18 , A61K39/00 , A61K39/395 , G01N33/50 , G01N33/574
摘要： 미드카인(Midkine) 저해제또는미드카인저해제와테모졸로마이드(Temozolomide)의조합을유효성분으로포함하는뇌종양의치료및/또는예방을위한약학조성물, 및미드카인저해제의테모졸로마이드치료및/또는방사선치료에대한저항성극복을위한용도가제공된다.
摘要翻译：提供：用于治疗和/或预防脑肿瘤的药物组合物，其含有作为活性成分的Midkine抑制剂或Midkine抑制剂和替莫唑胺的组合; 以及使用Midkine抑制剂来克服对替莫唑胺治疗和/或放疗的抗性。

2. 发明申请

WO2012050365A3 BIOMARKER FOR DIAGNOSING GLIOBLASTOMA OR PREDICTING PROGNOSIS OF GLIOBLASTOMA PATIENTS, AND USE THEREOF 审中-公开
公开(公告)号：WO2012050365A3
公开(公告)日：2012-11-01
申请号：PCT/KR2011007592
申请日：2011-10-12
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION , NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
发明人： NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： G01N33/57407
摘要： The present invention relates to a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients, and a use thereof, and more specifically, to an analysis method of a protein comprising the step of measuring the expression amount of the protein to provide the information necessary for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients by utilizing a protein selected from the group consisting of survivin, cyclinE, DCC, TGF-ß, CDC25B, Histone H1, p-EGFR, p-VEGFR2/3 and p16 as a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients. Since the proteins discovered through the analysis of the present invention can be applied to predict the prognosis of glioblastoma patients, a kit can be provided for predicting the prognosis of glioblastoma patients using the same and to apply the discovered proteins to develop a novel target therapy with respect to the proteins and an anticancer drug. As a result, the biomarker would also have a great ripple effect on the related industry fields, and is thus useful.

3. 发明专利

CA2883922A1 METHOD FOR PROLIFERATING STEM CELLS BY ACTIVATING NOTCH SIGNALING 未知
公开(公告)号：CA2883922A1
公开(公告)日：2011-08-11
申请号：CA2883922
申请日：2011-02-01
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： NAM DO HYUN , HONG SEUNG CHYUL , KANG BONG GU , JOO KYEUNG MIN
IPC分类号： C12N5/10 , A61K35/30 , C12N5/0797 , C12N15/12 , C12N15/85 , C12N15/86
摘要： The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway, stern cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

4. 发明专利

SG10201903658QA PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM 未知
公开(公告)号：SG10201903658QA
公开(公告)日：2019-05-30
申请号：SG10201903658Q
申请日：2013-12-11
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： NAM DO HYUN , JOO KYEUNG MIN
摘要： PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM The present invention relates to a personalized anti-cancer agent screening system, to a method for screening a personalized anti-cancer agent using said personalized anti-cancer agent screening system, and to a personalized anti-cancer agent screening apparatus. The personalized anti-cancer agent screening system of the present invention may not only select, from among a variety of candidate anti-cancer agents, the anti-cancer agent which exhibits optimum anti-cancer activity against a target patient- derived cancer cell but also may check in advance the treatment response which may be obtained when the selected anti-cancer agent is administered into the body of the patient. Thus, the personalized anti-cancer agent screening system of the present invention may not only reduce the trial and error and risk accompanied by a cancer treatment but also reduce the cost and time required for the treatment. FIG. -29-

5. 发明专利

CA2883922C METHOD FOR PROLIFERATING STEM CELLS BY ACTIVATING NOTCH SIGNALING 未知
公开(公告)号：CA2883922C
公开(公告)日：2019-08-27
申请号：CA2883922
申请日：2011-02-01
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： NAM DO HYUN , HONG SEUNG CHYUL , KANG BONG GU , JOO KYEUNG MIN
IPC分类号： C12N5/10 , A61K35/30 , C12N5/0797 , C12N15/12 , C12N15/85 , C12N15/86
摘要： The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway, stern cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

6. 发明专利

AU2016346595A1 Antibody to be cross-linked to human and mouse Sema3A, and use thereof 未知
公开(公告)号：AU2016346595A1
公开(公告)日：2018-06-14
申请号：AU2016346595
申请日：2016-10-26
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION , PANGEN BIOTECH INC
发明人： NAM DO HYUN , SHIN YONG JAE , LEE JAE HYUN
IPC分类号： C07K16/18 , A61K39/395
摘要： The present invention provides an antibody having the ability to be cross-linked to human Sema3A and mouse Sema3A. The antibody of the present invention can be used as a therapeutic antibody for inhibiting Sema3A in various carcinomas in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as an agent, in addition to being used as an anticancer drug, for treating associated diseases. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas, by using high anti-Sema3A binding and Sema3A function inhibition caused thereby, and inhibits the migration of cancer cells by inhibiting the phosphorylation of ERK among the downstream signaling materials of Sema3A, thereby being very effective in cancer prevention and treatment.

7. 发明专利

ES2606544T3 Método para provocar la proliferación de células madre mediante la activación de la señalización de Notch 未知
公开(公告)号：ES2606544T3
公开(公告)日：2017-03-24
申请号：ES11740024
申请日：2011-02-01
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： NAM DO HYUN , HONG SEUNG CHYUL , KANG BONG GU , JOO KYEUNG MIN
IPC分类号： C12N5/0797 , A61K35/30 , A61P25/00 , C12N5/10 , C12N15/12 , C12N15/86
摘要： Un método in vitro para aumentar la proliferación de células madre neurales que comprende una etapa de transfectar dichas células madre neurales con un gen que activa la señalización de Notch y cultivar las células madre neurales, en donde el gen codifica el NICD (Dominio IntraCelular Notch) que tiene una secuencia de aminoácidos expuesta en SEQ ID NO. 2, y la célula transfectada muestra una mayor proliferación comparado con la célula no transfectada.

8. 发明专利

SG11201508678SA METHOD FOR PREPARING PATIENT-SPECIFIC GLIOBLASTOMA ANIMAL MODEL, AND USE THEREOF 未知
公开(公告)号：SG11201508678SA
公开(公告)日：2015-11-27
申请号：SG11201508678S
申请日：2013-06-21
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
发明人： NAM DO HYUN , JIN JU YUON , JOO KYEUNG MIN
IPC分类号： A01K67/027 , C12N15/09 , G01N33/15
摘要： The present invention relates to a method for producing a glioblastoma mouse model, comprising the steps of: (a) dividing a glioblastoma tissue, isolated from a patient, into 4 or more sections, and collecting one or more pieces from each of the sections; (b) dissociating a mixture of the collected pieces into glioblastoma cells as single cells; and (c) orthotopically transplanting a graft sample, which contains the glioblastoma cells obtained in step (b), into the brain of an immunodeficient mouse. The present invention also relates to a mouse model produced by the method, a method of screening a glioblastoma therapeutic agent using the mouse model, and a method of providing information for selection of a patient-specific glioblastoma therapy using the mouse model. The glioblastoma mouse model according to the present invention shows the same genetic, morphological and pathological characteristics as those of the parental tumor, and thus it makes possible to screen a patient-specific glioblastoma therapeutic agent or select a safer and more effective patient-specific glioblastoma therapy.

9. 发明申请

WO2012050365A2 BIOMARKER FOR DIAGNOSING GLIOBLASTOMA OR PREDICTING PROGNOSIS OF GLIOBLASTOMA PATIENTS, AND USE THEREOF 审中-公开
标题翻译：生物标志物用于诊断滑膜瘤或预测滑膜瘤患者的预后及其应用
公开(公告)号：WO2012050365A2
公开(公告)日：2012-04-19
申请号：PCT/KR2011007592
申请日：2011-10-12
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION , NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
发明人： NAM DO HYUN , KIM JONG HYUN , PARK KWAN , SHIN HYUNG JIN , HONG SEUNG CHYUL , LEE JUNG-IL , KONG DOO-SIK , SEOL HO JUN , SUH YEON-LIM
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： G01N33/57407
摘要： The present invention relates to a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients, and a use thereof, and more specifically, to an analysis method of a protein comprising the step of measuring the expression amount of the protein to provide the information necessary for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients by utilizing a protein selected from the group consisting of survivin, cyclinE, DCC, TGF-ß, CDC25B, Histone H1, p-EGFR, p-VEGFR2/3 and p16 as a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients. Since the proteins discovered through the analysis of the present invention can be applied to predict the prognosis of glioblastoma patients, a kit can be provided for predicting the prognosis of glioblastoma patients using the same and to apply the discovered proteins to develop a novel target therapy with respect to the proteins and an anticancer drug. As a result, the biomarker would also have a great ripple effect on the related industry fields, and is thus useful.
摘要翻译：本发明涉及用于诊断胶质母细胞瘤或预测胶质母细胞瘤患者的预后的生物标志物及其用途，并且更具体地涉及蛋白质的分析方法，所述方法包括测量蛋白质表达量以提供必要信息的步骤通过利用选自由生存素，细胞周期蛋白E，DCC，TGF-β，CDC25B，组蛋白H1，p-EGFR，p-VEGFR2 / 3和p16组成的组的蛋白质作为生物标志物来诊断胶质母细胞瘤或预测胶质母细胞瘤患者的预后诊断胶质母细胞瘤或预测胶质母细胞瘤患者的预后。由于通过本发明的分析发现的蛋白质可以用于预测成胶质细胞瘤患者的预后，因此可以提供试剂盒用于预测使用胶质母细胞瘤患者的成胶质细胞瘤患者的预后，并将所发现的蛋白质应用于开发新的靶向治疗尊重蛋白质和抗癌药物。因此，生物标志物也将在相关的工业领域产生巨大的连锁反应，因此是有用的。

10. 发明申请

WO2011096728A3 METHOD FOR PROLIFERATING STEM CELLS BY ACTIVATING C-MET/HGF SIGNALING AND NOTCH SIGNALING 审中-公开
标题翻译：通过激活C-MET / HGF信号和Notch信号增强干细胞的方法
公开(公告)号：WO2011096728A3
公开(公告)日：2012-02-02
申请号：PCT/KR2011000730
申请日：2011-02-01
申请人： SAMSUNG LIFE PUBLIC WELFARE FOUNDATION , NAM DO HYUN , HONG SEUNG CHYUL , KANG BONG GU , JOO KYEUNG MIN
发明人： NAM DO HYUN , HONG SEUNG CHYUL , KANG BONG GU , JOO KYEUNG MIN
IPC分类号： C12N5/0797 , A61K35/30 , A61P25/00 , C12N5/10 , C12N15/12 , C12N15/86
CPC分类号： C12N5/0623 , A61K35/30 , C12N15/86 , C12N2501/11 , C12N2501/115 , C12N2501/12 , C12N2501/405 , C12N2501/42 , C12N2510/00
摘要： The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.
摘要翻译：本发明涉及其中引入了激活信号传导的基因的干细胞和涉及增殖干细胞的方法。更具体地，本发明涉及通过用Notch细胞内结构域（NICD）转染干细胞以激活Notch信号传导途径或通过用c-MET转染干细胞来显着增加干细胞增殖能力的方法并用HGF配体蛋白处理转染的干细胞以激活c-MET / HGF信号通路。根据本发明，通过激活Notch信号传导途径或c-MET / HGF信号传导途径，可以大量产生具有优异增殖能力的干细胞。特别是由于体外难以培养的神经干细胞可以大量增殖，因此神经干细胞将更有用于制备治疗颅神经疾病的细胞治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式